ADReCS

Pharmaceutical Information

Drug Name	Isoniazid
Drug ID	BADD_D01204
Description	Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.
Indications and Usage	For the treatment of all forms of tuberculosis in which organisms are susceptible.
Marketing Status	approved; investigational
ATC Code	J04AC01
DrugBank ID	DB00951
KEGG ID	D00346
MeSH ID	D007538
PubChem ID	3767
TTD Drug ID	D09XQF
NDC Product Code	60687-553; 0555-0071; 71610-395; 83112-071; 50090-0410; 63187-978; 0555-0066; 68788-9405; 71610-108; 12785-0003; 50090-0370; 70518-0096; 70518-2576; 43063-463; 62135-550; 0781-3056; 12785-0002; 66639-914; 51079-083; 43367-0100; 71052-611; 46287-009; 71335-0275; 53002-2920
UNII	V83O1VOZ8L
Synonyms	Isoniazid \| Isonicotinic Acid Hydrazide \| Hydrazide, Isonicotinic Acid \| Phthivazide \| Phthivazid \| Isonicotinic Acid Vanillylidenehydrazide \| Acid Vanillylidenehydrazide, Isonicotinic \| Vanillylidenehydrazide, Isonicotinic Acid \| Ftivazide \| Tubazide \| Isonex

Chemical Information

Molecular Formula	C6H7N3O
CAS Registry Number	54-85-3
SMILES	C1=CN=CC=C1C(=O)NN
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Respiratory disorder	22.02.07.002	0.002780%		-
Respiratory distress	22.02.01.012	0.005560%		-
Restlessness	17.02.05.021; 19.11.02.002	0.007505%
Rhabdomyolysis	15.05.05.002	0.044476%
Seizure	17.12.03.001	0.042252%
Sensory disturbance	17.02.07.006	-	-	-
Sensory loss	17.02.07.007	0.002780%		-
Serotonin syndrome	12.03.01.041; 15.05.04.016; 17.05.02.004	0.004170%		-
Shock	24.06.02.002	0.011119%		-
Sideroblastic anaemia	01.03.02.009	-	-	-
Sinus tachycardia	02.03.03.010	0.004170%
Skin discolouration	23.03.03.005	0.002780%		-
Skin disorder	23.03.03.007	0.006949%		-
Skin exfoliation	23.03.07.003	0.006949%		-
Skin hyperpigmentation	23.05.01.003	0.002780%
Skin lesion	23.03.03.010	0.004170%		-
Somnolence	17.02.04.006; 19.02.05.003	0.013899%
Speech disorder	17.02.08.003; 19.19.02.002; 22.12.03.027	0.006115%		-
Splenomegaly	01.09.02.001	-	-	-
Status epilepticus	17.12.03.005	0.023628%		-
Stevens-Johnson syndrome	10.01.01.045; 11.07.01.005; 12.03.01.014; 23.03.01.007	0.029187%
Stillbirth	08.04.01.006; 18.01.02.002	0.005560%		-
Stupor	17.02.04.007; 19.02.05.004	0.002780%		-
Suicide attempt	19.12.01.004	0.038917%
Syncope	02.11.04.015; 17.02.04.008; 24.06.02.012	0.006949%
Systemic lupus erythematosus	10.04.03.004; 15.06.02.003; 23.03.02.006	0.002780%		-
Tachycardia	02.03.02.007	0.012509%		-
Therapeutic response increased	08.06.01.021	-	-	-
Thrombocytopenia	01.08.01.002	0.016679%		-
Thrombocytopenic purpura	01.08.01.003; 23.06.01.007	0.002780%		-

The 8th Page First Pre 8 9 10 11 Next Last Total 11 Pages